Is Hormone Therapy + Everolimus Effective for Breast Cancer?

Is Hormone Therapy + Everolimus Effective for Breast Cancer?

Formerly certified by Japan's Ministry of Foreign Affairs Medical Visa Guarantee Agency B-66 Travel Services Arrangement Business License No. 35, Fukuoka Prefecture, Japan Japanese Medical Equipment Sales and Rental Business Management

Formerly certified by Japan's Ministry of Foreign Affairs Medical Visa Guarantee Agency B-66 Travel Services Arrangement Business License No. 35, Fukuoka Prefecture, Japan Japanese Medical Equipment Sales and Rental Business Management

Is Hormone Therapy + Everolimus Effective for Breast Cancer?

On May 23, 2022, Thomas Bachelot and colleagues from Centre Leon Berard published the results of a Phase III clinical trial (NCT01805271) on the efficacy and safety of hormone therapy + Everolimus as adjuvant therapy in high-risk, hormone receptor-positive, HER2-negative primary breast cancer patients in the Journal of Clinical Oncology.

This Phase III clinical trial randomized high-risk, hormone receptor-positive, HER2-negative primary breast cancer patients (N = 1278) into two groups: hormone therapy + Everolimus (continued for 2 years) and hormone therapy + placebo (continued for 2 years). The primary endpoint was progression-free survival.

The trial results showed that for the primary endpoint, the 3-year progression-free survival rate was: hormone therapy + Everolimus group 88% versus hormone therapy + placebo group 89%, showing no significant difference between the two groups. Regarding safety, the incidence of Grade 3 or higher adverse events was: hormone therapy + Everolimus group 29.9% versus hormone therapy + placebo group 15.9%. The rate of treatment discontinuation early in the trial was: hormone therapy + Everolimus group 53.4% versus hormone therapy + placebo group 22.3%.

Based on the Phase III clinical trial results, Thomas Bachelot and colleagues concluded that high-risk, hormone receptor-positive, HER2-negative primary breast cancer patients receiving hormone therapy + Everolimus as adjuvant therapy showed no significant improvement in progression-free survival, and approximately half of patients discontinued Everolimus treatment. They do not recommend Everolimus as adjuvant therapy.

Source: https://ascopubs.org/doi/abs/10.1200/JCO.21.02179

https://ascopubs.org/doi/abs/10.1200/JCO.21.02179

Medical Supporter was formerly certified as a medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).

Figure 1

Figure 2

Figure 3

Figure 4